An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR

Yanqin Niu1,2,*, Limin Zhang1,4, Huiling Qiu1,2,*, Yike Wu1, Zhiwei Wang3, Yujia Zai3, Lin Liu4, Junle Qu2, Kang Kang5 & Deming Gou1

We herein describe a simple, sensitive and specific method for analysis of circulating microRNAs (miRNA), termed S-Poly(T) Plus real-time PCR assay. This new method is based on our previously developed S-Poly(T) method, in which a unique S-Poly(T) primer is used during reverse-transcription to increase sensitivity and specificity. Further increased sensitivity and simplicity of S-Poly(T) Plus, in comparison with the S-Poly(T) method, were achieved by a single-step, multiple-stage reaction, where RNAs were polyadenylated and reverse-transcribed at the same time. The sensitivity of circulating miRNA detection was further improved by a modified method of total RNA isolation from serum/plasma, S/P miRsol, in which glycogen was used to increase the RNA yield. We validated our methods by quantifying miRNA expression profiles in the sera of the patients with pulmonary arterial hypertension associated with congenital heart disease. In conclusion, we developed a simple, sensitive, and specific method for detecting circulating miRNAs that allows the measurement of 266 miRNAs from 100 μl of serum or plasma. This method presents a promising tool for basic miRNA research and clinical diagnosis of human diseases based on miRNA biomarkers.

MicroRNAs (miRNAs) are small noncoding RNAs of ~22 nucleotide (nt) in length. They exist in almost all eukaryotic organisms and regulate gene expression by binding the 3′-untranslated region (3′-UTR) of target mRNAs1–3. Once a miRNA binds to its target mRNA, protein translation is inhibited or the mRNA is degraded via the miRNA-mediated RNA interference1,4. miRNAs are involved in cell differentiation, proliferation, and apoptosis and are implicated in many types of diseases5–9. miRNA expression profiles differ between healthy and diseased tissue10–12. Furthermore, miRNAs circulate in blood in a surprisingly high stable form13. Thus, circulating miRNAs have the remarkable potential to be developed as diagnostic, prognostic, and predictive biomarkers14–16.

The quantitative real-time PCR (qRT-PCR) has been recognized as one of the most sensitive techniques for miRNA detection17–19. Although other methods for quantifying miRNA are available, such as northern blotting, microarray or deep sequencing. Several approaches have been reported for detection of miRNAs using qRT-PCR. The most popular stem-loop method requires unique reverse transcription primers and a specific probe for each miRNA assay, and therefore it is fairly costly for screening of a large number of miRNAs17. The poly(A) method relies on adding a poly(A) tail to all types of RNAs, including miRNAs, and using a generic oligo(dT) primer for the reverse transcription (RT)20.
This method is capable of assaying miRNA expression in a high-throughput manner. However, it is less specific due to the non-specific reverse transcription. We have previously developed a novel S-Poly(T) method for miRNA qPCR assay, which is based on a uniquely designed S-Poly(T) reverse-transcription (RT) primer that contains six miRNA-specific bases and an oligo(dT) sequence. Although the sensitivity of the S-Poly(T) method is at least 4 times higher than that of the stem-loop and poly(A) methods, the S-Poly(T) method is still time-consuming and less-efficient since polyadenylation and reverse transcription are performed separately.

Therefore, there is a need for further optimization of miRNA quantitation using qRT-PCR, particularly for high-throughput screening or clinical samples with low miRNA levels, such as human serum/plasma (S/P). Based on our recently developed S-Poly(T) method, here we describe an improved method for detecting circulating miRNAs, termed S-Poly(T) Plus. The novelty of this approach is the combination of polyadenylation and reverse transcription into one step with retaining the S-Poly(T) primer. We optimized the experimental protocol for the S-Poly(T) Plus method. We also validated this method by quantifying miRNA expression profiles in the sera of pulmonary arterial hypertension (PAH) patients. We finally highlighted the strengths and limitations of this approach for clinical applications.

Results

Design of S-Poly(T) Plus method. The higher sensitivity and specificity of S-Poly(T) method are achieved by the application of the S-Poly(T) reverse-transcription (RT) primer. However, polyadenylation and reverse transcription in the S-Poly(T) method are carried out separately, which is time-consuming and costly. In the new version of S-Poly(T) Plus method, we combined polyadenylation and reverse transcription into a one-step, multiple-stage reaction, which increased efficiency. With the optimized reaction buffer, the reaction time was reduced to 65 min compared to 105 min in the two-step reaction of the S-Poly(T) method; The RNA amount from serum/plasma needed for the assay was decreased to one-fifth (see the Methods). The schematic diagram of the S-Poly(T) Plus protocol was depicted in the Fig. 1A. All the primers and probes used in this study are listed in Suppemental file 1.

Because PolyA polymerase and reverse transcriptase could work at 37 °C or 42 °C, we tested the effects of temperatures on the efficiency of one-step, multiple-stage reaction. As shown in Fig. 1B, we did not observe significant differences in human HEK293A cells for all the miRNAs we tested under the three temperature conditions. We recommend using the condition of 37 °C for 30 min and then 42 °C for 30 min to retain the respective optimal reaction temperature of both PolyA polymerase and reverse transcriptase.

We also used human HEK293A cells to test whether Poly(A) polymerase is required for the one-step, multiple-stage reaction. The Ct values of miRNA qRT-PCR assays decreased by 3.0 ~ 8.3 units when Poly(A) polymerase was neglected in the reaction mixture (Fig. 1C), indicating that the polyadenylation step is critical for the improvement of sensitivity in S-Poly(T) Plus method.

Sensitivity and dynamic range of S-Poly(T) Plus. To demonstrate the improvement of the new method, the sensitivity between S-Poly(T) and S-Poly(T) Plus was compared. We first determined the expression levels of six miRNAs (miR-103a-3p, miR-27b-3p, miR-126-3p, miR-34b-5p, miR-223-3p, and miR-150-5p) and a snoRNA (SNORD44) in human HEK293A cells. The results showed that the Ct values of all the miRNAs as assayed by S-Poly(T) Plus were smaller than those by S-Poly(T) method.

miR-223-3p showed the largest reduction in Ct value (3.07) and SNORD44 the smallest reduction (0.52) respectively. However, the regression lines of S-Poly(T) Plus were below those of S-Poly(T) method and there were 1.0 ~ 5.2 units difference in Ct value between two methods, indicating the increased sensitivity of S-Poly(T) Plus method.

We also tested the sensitivity of S-Poly(T) Plus using human serum samples. As shown in Fig. 2B, all the Ct values of six human miRNAs (miR-103a-3p, miR-27b-3p, miR-126-3p, miR-223-3p, and miR-150-5p) and a spiked-in Caenorhabditis elegans cel-miR-54-5p were significantly reduced using S-Poly(T) Plus when compared to those using S-Poly(T) method. Similar to HEK293A cells, miR-223-3p displayed the largest difference in Ct value (2.00), and miR-27b-3p the smallest (1.11), with 2.2 ~ 4.0-fold differences in sensitivity between S-Poly(T) and S-Poly(T) Plus methods.

We further evaluated the dynamic range of S-Poly(T) Plus. Six miRNAs (miR-92a-3p, miR-16-5p, miR-27b-3p, miR-210-3p, miR-103a-3p and miR-126-3p) and two snoRNAs (SNORD44 and SNORD47) were selected for this purpose. Total RNAs from HEK293A cells ranged from 2.5 ng (original) to 0.8 pg (diluted 5 times) were used for each miRNA detection. As shown in Fig. 3, the correlation coefficients (R²) produced by S-Poly(T) Plus and S-Poly(T) methods were 0.9933 ~ 0.9991 and 0.9745 ~ 0.9968, respectively. However, the regression lines of S-Poly(T) Plus were below those of S-Poly(T) method and there were 1.0 ~ 5.2 units difference in Ct value between two methods, indicating the increased sensitivity of S-Poly(T) Plus.

Human serum samples were further used to evaluate the dynamic range of S-Poly(T) Plus. Four miRNAs (miR-27-3p, miR-103a-3p, miR-126-3p and miR-150-5p) and a spiked-in cel-miR-54-5p were tested. We observed an excellent linear relationship between total RNA inputs and Ct values with R² ranging between 0.9536 and 0.9972. Typically, 0.075 μl (original) ~ 0.3 nl (duplicated 4 times) of initial serum RNA, corresponding to 0.38 μl ~ 1.5 nl of human serum sample, was sufficient for detection of certain miRNA using S-Poly(T) Plus (Fig. 4).
Optimization of RNA isolation. For circulating miRNA assay, total RNAs isolation from serum/plasma samples is very critical. To increase the yield of RNA isolation from serum or plasma samples, various concentrations of glycogen were added during the precipitation step of RNA extraction. We found that the optimized concentrations of glycogen were 1.875 ~ 15 μg/ml for S-Poly(T) method and 1.875 ~ 120 μg/ml for S-Poly(T) Plus (Fig. 5A,B). There was no significant signal detected in the controls without reverse transcriptase (-RT) using both S-Poly(T) and S-Poly(T) Plus methods. The smaller Ct values and a wider concentration range of glycogen suitable for RNA precipitation proved that the S-Poly(T) Plus assay was more sensitive and stable than the S-Poly(T) method. We routinely use 15 μg/ml of glycogen for RNA extraction for both S-Poly(T) and S-Poly(T) Plus methods and we named our RNA extraction method for serum/plasma samples S/P miRsol.

A previous study reported that an additional extraction of organic layer of serum samples can increase RNA yield when the amounts of samples are limited22. After the first extraction of RNAs as described above, we added 500 μl of water to the organic phase and collected the aqueous phase as the second extraction of RNAs after mixing and centrifugation. Using S-Poly(T) Plus method, we detected significant signals of the second extracted RNAs in miRNA qRT-PCR assay although the Ct values were 0.42 ~ 1.58 units larger than those of the first-extracted RNAs (Fig. 5C).

We next compared our S/P miRsol with two commercially available RNA isolation kits, miReasy Mini Kit (Qiagen) and mirVana PARIS Kit (Ambion). Due to interference of glycogen on the absorbance of
Figure 2. Comparison of sensitivity in miRNA assay between S-Poly(T) and S-Poly(T) Plus methods. (A) The expression levels of miR-103a-3p, miR-27b-3p, miR-126-3p, miR-34b-5p, miR-223-3p, miR-150-5p and SNORD44 were determined using total RNAs isolated from human HEK293A cells. (B) The expression levels of five human miRNAs of miR-103a-3p, miR-27b-3p, miR-126-3p, miR-223-3p, miR-150-5p and a spiked-in Caenorhabditis elegans miRNA cel-miR-54-5p were measured using total RNAs prepared from 24 healthy human serum mixture.

Figure 3. The correlation between total RNA inputs and threshold cycle (Ct) values of HEK293A cells as determined by S-Poly (T) and S-Poly (T) Plus methods. Total RNAs were isolated from human HEK293A cells. The RNA inputs ranged from 2.5 ng (original) to 0.8 pg (diluted 5^5 times) for each real-time PCR reaction. (A) miR-92a-3p, (B) miR-16-5p, (C) miR-27b-3p, (D) miR-210-3p, (E) miR-103a-3p, (F) miR-126-3p, (G) SNORD44 and (H) SNORD47.
RNA, the concentration of total RNAs cannot be measured correctly by spectrophotometer. Therefore, we evaluated the efficiency of RNA extraction among different methods based on Ct values measured by qPCR using an equal volume of initial serum RNA, corresponding to 0.38 µl ~ 1.5 nl of human serum sample were used in each real-time PCR reaction. The Ct values using S/P miRsol were decreased by 1.23 ~ 2.92 units compared to the miReasy Mini Kit and mirVana PARIS Kit, indicating that our method was more effective in serum RNA recovery for circulating miRNA assay (Fig. 6).

**microRNA expression profiling in CHD-PAH.** miRNAs can be used as potential biomarkers for many human diseases. We tested the utility of S/P miRsol and S-Poly(T) Plus in clinical applications by determining miRNA profiles in sera. A total of 31 human miRNAs possibly related to pulmonary arterial
hypertension (PAH) were selected based on previous reports (Supplemental file 2). The cel-miR-54-5p was used as a spiked-in normalization control. We first performed a first screen by pooling serum samples of 24 healthy subjects and 24 patients with CHD-PAH and fourteen miRNAs (miR-451a, miR-9, miR-424, miR-223, miR-204, miR-150, miR-328, miR-21, miR-34a, miR-34b, miR-26a, miR-27b, miR-126 and miR-20a) changed more than 1.5-fold. These miRNAs were further validated in each of the sera from 24 CHD-PAH patients and 24 healthy subjects individually. We found that two miRNAs (miR-20a-5p and miR-451a) were significantly up-regulated and five miRNAs (miR-204-5p, miR-424-5p, miR-126-3p, miR-26a-5p and miR-9-5p) were significantly down-regulated in CHD-PAH sera compared to the healthy controls (Fig. 7).

Taken all together, we developed an extremely sensitive and practical protocol for circulating miRNA detection by combining the S/P miRsol RNA extraction and the S-poly(T) Plus miRNA detection methods. If losses during the whole procedure are ignored, 100 \( \mu l \) of serum or plasma can be used to detect 266 miRNAs (Fig. 8).

**Discussion**

The circulating miRNAs have the potential to be used as biomarkers in the diagnosis of human diseases\(^{23,24}\). In our previously reported S-Poly(T) method, a S-Poly(T) primer consisting of an oligo(dT)\(_{11}\) sequence and six miRNA-specific bases is used during reverse transcription, thereby providing higher binding strength and thermodynamic stability between RT primer and miRNA template. The sensitivity of S-Poly(T) assay was at least 4-fold higher than that of the widely used Stem-loop method\(^{21}\).

In the S-Poly(T) Plus assay reported in this study, RNAs were polyadenylated and reverse-transcribed with the S-Poly(T) primer in a single-step reaction. The sensitivity was increased by at least one fold compared to the S-Poly(T) method. The improved sensitivity could be due to the larger RNA substrate concentration in mixture reaction. In S-Poly(T) Plus method, 3 \( \mu l \) serum RNA was used in a 10\( \mu l \) polyA tailing/RT reaction mixture. In S-Poly(T) method, 7.5 \( \mu l \) serum RNA was first used in a 10\( \mu l \) of polyA tailing reaction mixture and only 2\( \mu l \) of the polyadenylation reaction product containing 1.5\( \mu l \) serum RNA was then used in a 10\( \mu l \) of RT reaction mixture. Besides, less loss and lower risk of RNA degradation may also contribute to a higher sensitivity of S-Poly(T) Plus.

It is challenging to extract RNAs efficiently from serum/plasma because a tiny amount of RNAs is present in these samples. In this study, we successfully used the co-precipitant, glycogen to significantly improve the recovery of circulating miRNA (Figs 5 and 6). The S-Poly(T) Plus method is also cost-effective since all of the polyA-tailed RNA is used for RT reaction. By contrast, only one-fifth of polyadenylation product is added in the RT reaction in S-Poly(T) method. One hundred microliter of serum or plasma is sufficient for detecting 266 miRNAs using S-Poly(T) Plus method. Thus, the new method provides a powerful tool for miRNA screen when limited blood sample is available. For example, only limited amounts of blood can be drawn from transgenic mice; a droplet of blood can be used for point-of-care diagnosis of diseases.

PAH is characterized by vasculopathy due to increased vasoconstrictor tone and thrombosis. The structural changes are driven by excessive vascular cell growth and inflammation\(^{25}\). PAH occurs in different clinical conditions depending on associated diseases\(^{26}\), and it is commonly associated with congenital heart disease (15–30%)\(^{27}\). In the present study, the expression profiles of miRNAs in the sera of clinical CHD-PAH patients were validated by the S-Poly(T) Plus method. Our results revealed up-regulation of miR-20a-5p and miR-451a, and down-regulation of miR-204-5p, miR-424-5p, miR-126-3p, miR-26a-5p
and miR-9-5p in the sera of CHD-PAH patients. These miRNAs may be of potential use as early detection biomarkers for CHD-PAH.

Reduced miR-150 levels have been observed in idiopathic PAH patients\textsuperscript{23}. miR-210 is one of the validated miRNAs that are significantly induced by hypoxia in HPASMC, or other cell lines\textsuperscript{21,28}. However, we did not observe any changes of these two miRNAs in the CHD-PAH patients. The discrepancies are not entirely unexpected and could be the results of the differential pathobiology induced by different diseases, drugs, or hypoxia\textsuperscript{26}.

PAH is also characterized largely by enhanced proliferation and reduced apoptosis of PASMCs\textsuperscript{29}. We have previously reported that miR-20a-5p directly targets the PRKG1 gene, thereby promoting the proliferation and migration of PASMCs but inhibiting cell differentiation\textsuperscript{30}. We have also shown that miR-9-5p increases PAH-PASMC proliferation and resistance to apoptosis by enhancing the activity of NFAT via targeting KPNB1 and DYRK1B\textsuperscript{31}. The down-regulation of miR-204 is found in PAH-PASMCs

---

**Figure 7. Differentially expressed miRNAs in the sera of CHD-PAH patients and healthy individuals.**

The expression levels of miRNAs were determined by S-Poly(T) Plus in the sera of 24 CHD-PAH patients and 24 healthy controls. miRNA levels were normalized to spiked-in cel-miR-54-5p and represented in scatter plots. Data are shown as means ± SE, *p < 0.1 vs. healthy control, **p < 0.01 vs. healthy control, ***p < 0.001 vs. healthy controls.
and pulmonary delivering of miR-204 reduces disease severity in a PAH animal model. Other miRNAs among the 31 miRNAs selected for miRNA profiling in PAH have also been studied. For instance, the genetic ablation of miR-145 results in a significant decrease in PAH development in mouse models. miR-451 promotes migration of PASMCs, but interestingly, the genetic loss of miR-451 does not attenuate the development of PAH. This is probably because the pathway redundancy compensates for the loss of miR-451. In addition to PAH, cancer or other disease-specific miRNAs should further be explored for their clinical applications as reliable biomarkers.

In summary, the current study provides a simple, sensitive, and inexpensive miRNA profiling tool for detecting circulating miRNAs with the precise quantification. This tool could be used for diagnosis for a variety of human PAH, cancers or other diseases based on miRNA biomarkers.

Methods

Serum collection and cell culture. Human serum samples were collected from 24 healthy donors and 24 patients with CHD-PAH from the Yat-Sen Cardiovascular Hospital (Shenzhen, China). The blood samples were kept at room temperature for 1 h, and then centrifuged at 3,000 g for 10 min at 4 °C. The sera were stored at −80 °C. All procedures were carried out according to the approved guidelines. The Institutional Ethics Committee at the Sun Yat-Sen Cardiovascular Hospital (Shenzhen, China) approved the experiments. All participants were provided with written informed consent.

Human HEK293A cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO₂ condition.

S/P miRsol RNA extraction. Circulating RNAs were isolated from serum/plasma by S/P miRsol method developed in this study. Briefly, 1 ml of RNAiso-Plus (TaKaRa, Dalian, China) supplemented with 0.1 pM spiked-in Caenorhabditis elegans cel-miR-54-5p for normalization was added to 100 μl of serum or plasma and quickly vortexed thoroughly. Then 200 μl of chloroform was added and mixed by vigorous shaking for 20 s. The samples were incubated for 5 min at room temperature and centrifuged at 12,000 g for 15 min at 4 °C. A 500 μl aqueous phase was transferred into a fresh tube and mixed with 6 μl of glycogen (AppliChem, Darmstadt, Germany). An equal volume (506 μl) of isopropyl alcohol was added into the mixture and incubated at −20 °C for 10 min followed by centrifugation at 13,500 g for 10 min at 4 °C. The RNA pellet was washed with 1 ml of 75% ethanol and dissolved in 20 μl of RNase-free water. The same procedure was used to isolate total RNAs from cultured cells except that no spiked-in cel-miR-54-5p and glycogen were used.

In certain experiments, second extraction was performed to see whether additional RNAs can be recovered from serum/plasma samples. Briefly, after 500 μl of aqueous phase was removed for the first extraction, an equal volume (500 μl) of RNase-free water was added to the organic phase. A 500 μl aqueous phase was collected as the second extraction of RNAs after mixing and centrifugation.

Polyadenylation and reverse transcription. For the S-Poly(T) method, total RNA from cultured cells or serum was polyadenylated with the Poly(A) Polymerase Tailing Kit (Epicentre, Madison, USA) according to manufacturer's instruction. Briefly, 1 μl of 10 × poly(A) polymerase reaction buffer, 1 μl of 10 mM ATP and 0.8 units of Poly(A) polymerase were added to 500 ng total RNA from cells/tissues or 7.5 μl of 20 μl total RNAs isolated from 100 μl serum/plasma. The reaction mixture was made to a total volume of 10 μl with RNase-free water and incubated at 37 °C for 30 min and then 65 °C for 5 min. The
tailed miRNA was reverse-transcribed in a 10 μl reaction containing 2 μl of polyadenylation reaction product, 1 μl of 0.5 μM RT primer, 2.5 μl of 2 mM dNTP, 1 μl of MMLV HP RT 10 × reaction buffer, and 100 units of MMLV High Performance Reverse Transcriptase (Epiconcept, Madison, WI, USA). The reaction was incubated at 42 °C for 60 min and terminated at 70 °C for 10 min.

In the S-Poly(T) Plus method, polyadenylation and reverse transcription were performed in a single step with an optimized buffer. In brief, the following components were added to 10 μl of reaction mixture: 100 ng of total RNAs from cells/tissues or 3 μl of 20 μl total RNAs isolated from 100 μl of serum/plasma, 2.5 μl of 4 × reaction buffer mix containing ATP and dNTPs, 1 μl of 0.5 μM RT primer and 1 μl of polyA/RT enzyme mix (with 0.8 units of Poly(A) polymerase and 100 units of MMLV High Performance Reverse Transcriptase). The reaction was incubated at 37 °C for 30 min, 42 °C for 30 min, and then terminated at 75 °C for 5 min.

To compare the sensitivity and dynamic range of two methods, the serially diluted RNAs were used in the polyadenylation and reverse transcription reaction. For RNA samples from cells, the amounts of RNAs for each qPCR reaction ranged from 2.5 ng (original) to 0.8 pg (diluted 55 times). For serum RNA controls. Relative quantities of miRNAs were calculated using the 2ΔΔCt method with cel-miR-54-5p spiked-in as a normalization control. Two-tailed Student’s t test was used for statistical analysis using the GraphPad Prism 5. Data was shown as means ± SE (standard error).

**References**

1. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. cell 116, 281–297 (2004).
2. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522–531 (2004).
3. Lim, L. P., Glasner, M. E., Yekta, S., Burge, C. B. & Bartel, D. P. Vertebrate microRNA genes. Science 299, 1540–1544 (2003).
4. Bader, A. G., Brown, D. & Winkler, M. The promise of microRNA replacement therapy. PloS one 116, e48536 (2012).
5. Bushati, N. & Cohen, S. M. microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175–205 (2007).
6. Chen, J.-F. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile. Cell Mol. Biol. 56, OL1299–1317 (2010).
7. Croce, C. M. & Calin, G. A. miRNAs, cancer, and stem cell division. Cell 122, 6–7 (2005).
8. Di Maio, A. et al. A novel real-time PCR assay of microRNAs using S-Poly (T), a specific oligo (dT) reverse transcription primer. BMC Genomics 12, 435 (2011).
9. Diakos, C. et al. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 116, 4885–4893 (2010).
10. Jensen, S. G. et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 12, 435 (2011).
11. Renwick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55–59 (2009).
12. Wang, K. et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. P. Nat. A. Sci. 106, 4402–4407 (2009).
13. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. P. Nat. A. Sci. 105, 10513–10518 (2008).
14. Gupta, S. K., Bang, C. & Thum, T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ. Cardiovasc. Gene. 3, 484–488 (2010).
15. Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12, R90 (2010).
16. Toiyama, Y. et al. Serum miR 200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 259, 735–743 (2014).
17. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179–e179 (2005).
18. Jiang, J., Lee, E. J., Gusev, Y. & Schmittgen, T. D. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394–5403 (2005).
19. Reichenstein, L., Aizenberg, N., Goshen, M., Bentwich, Z. & Avni, Y. S. A novel qPCR assay for viral encoded microRNAs. J. Virol. methods 163, 323–328 (2010).
20. Design, R.-F. F. P. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques 39, 519–525 (2005).
21. Kang, K. et al. A novel real-time PCR assay of microRNAs using S-Poly (T), a specific oligo (dT) reverse transcription primer with excellent sensitivity and specificity. PloS one 7, e48536 (2012).
22. Burgos, K. L. et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 19, 712–722 (2013).
23. Rhodes, C. J. et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *Am. J. Resp. Crit. Care*. 187, 294–302 (2013).

24. Wei, C. et al. Circulating miRNAs as potential marker for pulmonary hypertension. *PLoS One* 8, e64396 (2013).

25. Schermuly, R. T.; Ghofrani, H. A.; Wilkins, M. R. & Gromminger, F. Mechanisms of disease: pulmonary arterial hypertension. *Nat. Rev. Cardiol.* 8, 443–455 (2011).

26. Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. *J. Am. Coll. Cardiol.* 54, S43–S54 (2009).

27. Landsberg, M. J. Congenital heart disease associated pulmonary arterial hypertension. *Clin. Chest Med.* 28, 243–253 (2007).

28. Camps, C. et al. MiR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin. Cancer Res.* 14, 1340–1348 (2008).

29. Mandegar, M. et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. *Microvasc. Res.* 68, 75–103 (2004).

30. Zeng, Y. et al. MiR-20a regulates the PKR1G1 gene by targeting its coding region in pulmonary arterial smooth muscle cells. *FEBS Lett.* 588, 4673–4685 (2014).

31. Zeng, Y. et al. MicroRNA-9 enhances the transactivation of nuclear factor of activated T cells by targeting KPNB1 and Dyrk1B. *Am. J. Physiol-Cell Ph.* 308, C720–C728 (2015).

32. Courboulin, A. et al. Role for miR-204 in human pulmonary arterial hypertension. *J. Exp. Med.* 208, 535–548 (2011).

33. Caruso, P. et al. A role for miR-145 in pulmonary arterial hypertension evidence from mouse models and patient samples. *Circ. Res.* 111, 290–300 (2012).

34. Caruso, P. et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. *Arterioscl. Throm. Vasc. Dis.* 30, 716–723 (2010).

35. Grant, J. S. et al. Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. *Pulm. Circ.* 3, 840 (2013).

36. Qin, X. et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. *P. Natl. Acad. Sci. U. S. A.* 107, 3240–3244 (2010).

37. Sarkar, I. et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. *Am. J. Physiol-Lung C.* 299, L861–L871 (2010).

38. Shanshan, L. et al. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. *Biochem. J.* 452, 281–291 (2013).

39. Cheng, Y. et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. *Circ. Res.* 105, 158–166 (2009).

40. Mizuno, S. et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. *Am. J. Physiol-Lung C.* 300, L753–L761 (2011).

41. Guo, L. et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C. *Hypertension* 59, 1006–1013 (2012).

42. Bockmeyer, C. L. et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. *J. Heart Lung Transpl.* 31, 764–772 (2012).

43. Kim, J. et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. *Nat. Med.* 19, 74–82 (2013).

44. Kang, K. et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. *J. Biol. Chem.* 288, 25414–25427 (2013).

45. Vincik, J. et al. MiR-223 Improves Experimental Pulmonary Arterial Hypertension. *Circulation* 130, A18653–A18653 (2014).

**Acknowledgements**

This study was supported in part by Natural Science Foundation of China 81170047, 81370151 and 81570046 to D.G. and 31571199 to K.K. National Basic Research Program of China 973 Program 2012CB124701, Shenzhen Overseas High-Level Talents Innovation Program YFZZ20111009 to D.G., Shenzhen Municipal Basic Research Program JCYJ2013032912057746 to K.K., and Shenzhen University Foundation 201562 to K.K.

**Author Contributions**

Conceived and designed the experiment: Deming Gou and Kang Kang; collected the blood samples: Z.W. and Y.Z.; conducted the experiments: L.Z. and Y.W.; performed data analysis: Y.N. and L.Z.; wrote the manuscript: Y.N., H.Q., L.L., J.Q., K.K. and D.G.; All the authors have reviewed the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

**How to cite this article**: Niu, Y. et al. An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR. *Sci. Rep.* 5, 15100; doi: 10.1038/srep15100 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/